Shots:

• The P-IIIb SEAVUE study involves assessing Stelara(6 mg/kg- IV at baseline- then 90mg- SC- q8w) vs Humira (160/80mg- SC at baseline- then 40mg- SC- q2w) in the treatment of 386 biologic-naïve patients in a ratio (1:1) with mod. to sev. active CD
• The data demonstrated high rates of clinical remission- corticosteroid-free remission- clinical response- and endoscopic response through 1yr.- although the 1EPs of statistical superiority was not demonstrated
• Additional abstracts of data are also being presented at DDW- which include safety of Stelara in IBD along with long term data of Stelara in the IM-UNITI study with RWE of the therapy for CD

  Ref: J&J | Image: Janssen